CATT, Hopkins analysis add fervor to ranibizumab vs. bevacizumab debate.

The article focuses on the debate regarding the use of bevacizumab and ranibizumab that was spurred by the analysis of Johns Hopkins Medicare and the Comparison of Age-Related Macular Degeneration (AMD) Treatment Trials (CATT) of the National Eye Institute. It mentions that ranibizumab is approved by the Food and Drug Administration (FDA) while bevacizumab is not. It also notes that 1,185 patients in the CATT study were given intraviteral injections of bevacizumab and ranibizumab.